SCHEMBL4025618

SCHEMBL4025618

COc1ccc2c(c1)C1(CCN(C(=O)C3=Cc4ccccc4C3C)CC1)OC2=O

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ AVPR1A P37288 4/20 0.47
▸ HRH3 Q9Y5N1 2/20 0.46
▸ NPY5R Q15761 5/20 0.44
▸ LMNA P02545 1/20 0.36
▸ THRB P10828 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ USP2 O75604 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ SCN5A Q14524 1/20 0.36
▸ SCN9A Q15858 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ HIF1A Q16665 1/20 0.36
▸ MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4980584 0.79 AVPR1A (0.52) AVPR1AHRH3NPY5RLMNAPOLB
SCHEMBL3841971 0.76 HTR1A (0.49) AVPR1AHRH3NPY5RLMNAPOLB
SCHEMBL22058131 0.74 AVPR1A (0.55) AVPR1AHRH3NPY5RPOLBSMN1; SMN2
SCHEMBL3841668 0.74 HRH3 (0.49) AVPR1AHRH3NPY5RSMN1; SMN2CYP3A4
SCHEMBL2212786 0.74 AVPR1A (0.53) AVPR1AHRH3NPY5RLMNATHRB
SCHEMBL3840207 0.74 NPY5R (0.55) AVPR1AHRH3NPY5RPOLBSMN1; SMN2
SCHEMBL4984531 0.73 AVPR1A (0.52) AVPR1AHRH3NPY5RLMNAPOLB
SCHEMBL3842016 0.71 HTR1A (0.49) AVPR1AHRH3NPY5RLMNAPOLB
SCHEMBL3836464 0.70 HRH3 (0.49) AVPR1AHRH3NPY5RSMN1; SMN2CYP3A4
SCHEMBL2212222 0.70 DRD3 (0.56) AVPR1AHRH3NPY5RMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501432-B2 Spiro-piperidine derivatives HOFFMAN-LA ROCHE INC. (US) 2009-03-10 — — US disclosed
US-20080167333-A1 NEW SOLID FORMS OF [4-(3-FLUORO-5-TRIFLUOROMETHYL-PYRIDIN-2-YL)-PIPERAZIN-1-YL-[5-METHANESULFONYL-2-((S)-2,2,2-TRIFLUORO-1-METHYL-ETHOXY)-PHENYL]-METHANONE F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2008-07-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167333-A1 NEW SOLID FORMS OF [4-(3-FLUORO-5-TRIFLUOROMETHYL-PYRIDIN-2-YL)-PIPERAZIN-1-YL-[5-METHANESULFONYL-2-((S)-2,2,2-TRIFLUORO-1-METHYL-ETHOXY)-PHENYL]-METHANONE HTR1A, HTR5A, ADRA1A AVPR1A 7/4885HRH3 340/4885NPY5R 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback